Effect of Myo‐Inositol Treatment on Serum Asprosin Levels of Pregnant Women: A Prospective Randomized Controlled Pilot Study
Journal of Pregnancy · 2025
DOI: 10.1155/jp/8816154 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Journal of Pregnancy, 2025. Verfasst von Ali Cenk Özay und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Obstetrics and Gynecology, Cyprus International University, Nicosia, Cyprus, ciu.edu.tr. Hauptthemen laut MEDLINE: Inositol, Fibrillin-1. Die Arbeit nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Objectives
Asprosin is a newly discovered adipokine associated with insulin resistance and diabetes mellitus. Currently, its role during gestation is under investigation, as asprosin seems to increase during pregnancy, contributing to the onset of complications, like gestational diabetes. Considering the beneficial effects of myo‐inositol to support the physiological pregnancy, recovering and preventing adverse maternal and fetal outcomes, we aimed to evaluate the effects of its supplementation on serum asprosin levels in pregnant women.
Design
We enrolled 40 patients at the early stages of pregnancy and randomly distributed them to a study group, which received 2‐g myo‐inositol and 200‐ μ g folic acid twice a day, or to a control group, which received the sole folic acid.
Results
After 20–22 weeks of treatment, we recorded a decrease of serum asprosin values as well as of HOMA‐IR index in the group supplemented with myo‐inositol, while the group that took only folic acid showed an increase in asprosin levels and no worsening of insulin resistance indices (HOMA‐IR index).
Limitations
The small number of patients could be a limitation of the study.
Conclusions
Asprosin may be modulated by myo‐inositol. This opens the possibility of considering this adipokine as a useful marker of insulin resistance to assess in pregnant women and to efficaciously target in clinical practice. Trial Registration: ClinicalTrials.gov identifier: NCT05943158.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Obstetrics and Gynecology, Cyprus International University, Nicosia, Cyprus, ciu.edu.tr.
- The Experts Group on Inositol in Basic and Clinical Research and on PCOS (EGOI-PCOS), Rome, Italy.
- Department of Biochemistry, Near East University, Nicosia, Cyprus, neu.edu.tr.
- Department of Medical Biology, Adıyaman University, Adıyaman, Turkey, adiyaman.edu.tr.
- Department of Obstetrics and Gynecology, Santo Spirito Hospital, Rome, Italy.
- Systems Biology Group Lab, Rome, Italy.
ORCID-Profile: Ali Cenk Özay, Oğuz Han Edebal, Mario Montanino Oliva, Simona Dinicola, Vittorio Unfer
Zitieren
APA
Özay, A. C., Özay, Ö. E., Edebal, O. H., Özay, Y., Montanino Oliva, M., Dinicola, S., & Unfer, V. (2025). Effect of Myo‐Inositol Treatment on Serum Asprosin Levels of Pregnant Women: A Prospective Randomized Controlled Pilot Study. Journal of Pregnancy. https://doi.org/10.1155/jp/8816154
Vancouver
Özay AC, Özay ÖE, Edebal OH, Özay Y, Montanino Oliva M, Dinicola S, et al. Effect of Myo‐Inositol Treatment on Serum Asprosin Levels of Pregnant Women: A Prospective Randomized Controlled Pilot Study. Journal of Pregnancy. 2025. doi:10.1155/jp/8816154
BibTeX
@article{zay2025,
author = {Özay, Ali Cenk and Özay, Özlen Emekçi and Edebal, Oğuz Han and Özay, Yusuf and Montanino Oliva, Mario and Dinicola, Simona and Unfer, Vittorio},
title = {Effect of Myo‐Inositol Treatment on Serum Asprosin Levels of Pregnant Women: A Prospective Randomized Controlled Pilot Study},
journal = {Journal of Pregnancy},
year = {2025},
doi = {10.1155/jp/8816154}
}
EUVIMED